Abstract
Gastrointestinal stromal tumors are rare malignancies characterized by c-kit and PDGFR-α mutations targeted by imatinib. Pleural effusion is a very rare side effect of imatinib treatment. A 65-year-old female with metastatic gastrointestinal stromal tumor developed electrolyte imbalance, severe peripheral edema and progressively worsening dyspnea 2 months after starting imatinib. Having excluded cardiovascular and pulmonary disorders, imatinib was discontinued and prednisone 25 mg orally daily was begun. The patient's condition improved substantially over the next 48 h with a progressive decrease in dyspnea and a reduction in pleural effusion and peripheral edema. All side effects had resolved within 1 month. In view of the partial response obtained, the patient re-started imatinib after a 1-week interruption. Prednisone was maintained and there was no further toxicity.
| Original language | English |
|---|---|
| Pages (from-to) | 2423-2427 |
| Number of pages | 5 |
| Journal | Future Oncology |
| Volume | 10 |
| Issue number | 15 |
| DOIs | |
| Publication status | Published - Dec 1 2014 |
Fingerprint
Keywords
- gastrointestinal stromal tumor
- imatinib
- metastatic gastrointestinal stromal tumor
- pleural effusion
- toxicity
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib : Case report. / Bongiovanni, Alberto; Ricci, Marianna; Riva, Nada; Calpona, Sebastiano; Oboldi, Devil; Pieri, Federica; Cavaliere, Davide; Mercatali, Laura; Liverani, Chiara; La Manna, Federico; De Vita, Alessandro; Foca, Flavia; Gunelli, Erica; Amadori, Dino; Ibrahim, Toni.
In: Future Oncology, Vol. 10, No. 15, 01.12.2014, p. 2423-2427.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib
T2 - Case report
AU - Bongiovanni, Alberto
AU - Ricci, Marianna
AU - Riva, Nada
AU - Calpona, Sebastiano
AU - Oboldi, Devil
AU - Pieri, Federica
AU - Cavaliere, Davide
AU - Mercatali, Laura
AU - Liverani, Chiara
AU - La Manna, Federico
AU - De Vita, Alessandro
AU - Foca, Flavia
AU - Gunelli, Erica
AU - Amadori, Dino
AU - Ibrahim, Toni
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Gastrointestinal stromal tumors are rare malignancies characterized by c-kit and PDGFR-α mutations targeted by imatinib. Pleural effusion is a very rare side effect of imatinib treatment. A 65-year-old female with metastatic gastrointestinal stromal tumor developed electrolyte imbalance, severe peripheral edema and progressively worsening dyspnea 2 months after starting imatinib. Having excluded cardiovascular and pulmonary disorders, imatinib was discontinued and prednisone 25 mg orally daily was begun. The patient's condition improved substantially over the next 48 h with a progressive decrease in dyspnea and a reduction in pleural effusion and peripheral edema. All side effects had resolved within 1 month. In view of the partial response obtained, the patient re-started imatinib after a 1-week interruption. Prednisone was maintained and there was no further toxicity.
AB - Gastrointestinal stromal tumors are rare malignancies characterized by c-kit and PDGFR-α mutations targeted by imatinib. Pleural effusion is a very rare side effect of imatinib treatment. A 65-year-old female with metastatic gastrointestinal stromal tumor developed electrolyte imbalance, severe peripheral edema and progressively worsening dyspnea 2 months after starting imatinib. Having excluded cardiovascular and pulmonary disorders, imatinib was discontinued and prednisone 25 mg orally daily was begun. The patient's condition improved substantially over the next 48 h with a progressive decrease in dyspnea and a reduction in pleural effusion and peripheral edema. All side effects had resolved within 1 month. In view of the partial response obtained, the patient re-started imatinib after a 1-week interruption. Prednisone was maintained and there was no further toxicity.
KW - gastrointestinal stromal tumor
KW - imatinib
KW - metastatic gastrointestinal stromal tumor
KW - pleural effusion
KW - toxicity
UR - http://www.scopus.com/inward/record.url?scp=84920007574&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920007574&partnerID=8YFLogxK
U2 - 10.2217/fon.14.159
DO - 10.2217/fon.14.159
M3 - Article
C2 - 25525851
AN - SCOPUS:84920007574
VL - 10
SP - 2423
EP - 2427
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 15
ER -